Your browser doesn't support javascript.
loading
Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study.
Fournier, Damien; Carrière, Romain; Bour, Maxime; Grisot, Emilie; Triponney, Pauline; Muller, Cédric; Lemoine, Jérôme; Jeannot, Katy; Plésiat, Patrick.
Afiliación
  • Fournier D; Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Carrière R; Institut des Sciences Analytiques, UMR CNRS 5280, Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Bour M; Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Grisot E; Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Triponney P; Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Muller C; Smaltis SAS, Research and Development Department, Besançon, France.
  • Lemoine J; Institut des Sciences Analytiques, UMR CNRS 5280, Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Jeannot K; Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Plésiat P; UMR6249 Chrono-environnement, Faculté de Médecine-Pharmacie, Université Bourgogne-Franche Comté, Besançon, France.
Article en En | MEDLINE | ID: mdl-33199392
ABSTRACT
Resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam (C/T) were assessed on a collection of 420 nonredundant strains nonsusceptible to ceftazidime (MIC > 8 µg/ml) and/or imipenem (>4 µg/ml), collected by 36 French hospital laboratories over a one-month period (the GERPA study). Rates of C/T resistance (MIC > 4/4 µg/ml) were equal to 10% in this population (42/420 strains), and 23.2% (26/112) among the isolates resistant to both ceftazidime and imipenem. A first group of 21 strains (50%) was found to harbor various extended-spectrum ß-lactamases (1 OXA-14; 2 OXA-19; 1 OXA-35; 1 GES-9; and 3 PER-1), carbapenemases (2 GES-5; 1 IMP-8; and 8 VIM-2), or both (1 VIM-2/OXA-35 and 1 VIM-4/SHV-2a). All the strains of this group belonged to widely distributed epidemic clones (ST111, ST175, CC235, ST244, ST348, and ST654), and were highly resistant to almost all the antibiotics tested except colistin. A second group was composed of 16 (38%) isolates moderately resistant to C/T (MICs from 8/4 to 16/4 µg/ml), of which 7 were related to international clones (ST111, ST253, CC274, ST352, and ST386). As demonstrated by targeted mass spectrometry, cloxacillin-based inhibition tests, and gene blaPDC deletion experiments, this resistance phenotype was correlated with an extremely high production of cephalosporinase PDC. In part accounting for this strong PDC upregulation, genomic analyses revealed the presence of mutations in the regulator AmpR (D135N/G in 6 strains) and enzymes of the peptidoglycan recycling pathway, such as AmpD, PBP4, and Mpl (9 strains). Finally, all of the 5 (12%) remaining C/T-resistant strains (group 3) appeared to encode PDC variants with mutations known to improve the hydrolytic activity of the ß-lactamase toward ceftazidime and C/T (F147L, ΔL223-Y226, E247K, and N373I). Collectively, our results highlight the importance of both intrinsic and transferable mechanisms in C/T-resistant P. aeruginosa Which mutational events lead some clinical strains to massively produce the natural cephalosporinase PDC remains incompletely understood.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pseudomonas aeruginosa / Infecciones por Pseudomonas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pseudomonas aeruginosa / Infecciones por Pseudomonas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2021 Tipo del documento: Article País de afiliación: Francia